Altea, Amylin and Lilly to develop first transdermal exenatide
This article was originally published in Scrip
Altea Therapeutics has signed a deal worth up to $46 million with Amylin Pharmaceuticals and Lilly to develop and commercialise the first transdermal exenatide patch for type 2 diabetes. Lilly and Amylin market exenatide, a first-in-class GLP-1 analogue, as Byetta.
You may also be interested in...
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.
Gilead Sciences has reported a 24% increase in product sales to $1.8 billion for the first quarter following strong growth of its antiviral franchise. Net income was $855 million, an increase of 45%.